What is it about?
This study evaluates early reports on two novel treatments and their impact on the management of metastatic melanoma : 1) Ipilimumab which targets the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). 2) Vemurafenib (originally known as Plexxikon) targeting B-RAF-mutant melanomas
Featured Image
Read the Original
This page is a summary of: Latest developments in the treatment of melanoma: ‘a penicillin moment for cancer’?, Journal of the Royal Society of Medicine, June 2011, SAGE Publications,
DOI: 10.1258/jrsm.2011.100405.
You can read the full text:
Contributors
The following have contributed to this page
